Verification of the Epidemiology and Mortality of Rare Diseases in Taiwan With Real-world Evidence

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-09

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to explore the longitudinal incidence and prevalence trends of selected muscular and bone-related rare diseases, i.e., Familial Amyloidotic Polyneuropathy (FAP), Primary hyperoxaluria, Wilson's disease, Cystic fibrosis, Osteogenesis imperfecta, Porphyria, and Primary Paget disease, and analyze healthcare utilization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Establish a "Taiwan Rare Disorder Tissue Bank", to Collect and Repost Biological Samples and Disease Information From Patients With Rare Disorders

NCT01384305

Rare Disorders

UNKNOWN

Family History in Prostate Cancer Patients in Taiwan

NCT00155025

Prostate Cancer

UNKNOWN

A Long Term Follow up Study in Late-onset Pompe Disease

NCT00713245

Pompe Disease

UNKNOWN

Muscle Response to Enzyme Replacement Therapy in Pompe Disease

NCT00713453

Pompe Disease

UNKNOWN

A Long-term Study for the Outcome of Pompe Disease

NCT02399748

Pompe Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A rare disease (RD) means any disease that affects a small percentage of the population. According to the "Rare Disease and Orphan Drug Act" in 2000, RD is defined as the prevalence of lower than 10,000 people in Taiwan, or with special circumstances, and announced after review by the "Review Committee for Rare Diseases and Orphan Drugs". There are many different causes of RD, such as genetic and infection. Although researchers have made progress in learning how to diagnose, treat, and even prevent a variety of RD, but there is still much to do because most rare diseases have no treatments. Due to the low morbidity rate and fewer numbers of people who suffer from RD, patients have been impacted by a severe pathology and insufficiently recognized, diagnosed, and cured. However, prevalence, healthcare utilization, and economic impacts of rare diseases based on real-world evidence are still unknown in the world, especially in Taiwan. In 2020, there were 226 diseases officially proclaimed as RD and 17,592 patients in Taiwan, and approved 108 orphan drugs and 40 special nutrients for treating those patients to reduce their financial burden.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rare Diseases Epidemiology Morbidity Morality Comorbidities and Coexisting Conditions Health Care Utilization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Familial Amyloidotic Polyneuropathy

The Familial Amyloidotic Polyneuropathy patients are validated in the catastrophic illness certification.

longitudinal observational study

Intervention Type OTHER

longitudinal observational study

Osteogenesis imperfecta

The Osteogenesis imperfecta patients are validated in the catastrophic illness certification.

longitudinal observational study

Intervention Type OTHER

longitudinal observational study

(Acute Hepatic) Porphyria

The (Acute Hepatic) Porphyria patients are validated in the catastrophic illness certification.

longitudinal observational study

Intervention Type OTHER

longitudinal observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

longitudinal observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The RD patients were defined as at least two ambulatory care records or one inpatient record in one year with Familial Amyloidotic Polyneuropathy (FAP), Osteogenesis imperfecta, and Acute Hepatic Porphyria between 2009 and 2017.